Surge in Clinical Trials and Combination Therapies in PARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a revolutionary class of drugs in the treatment of cancer, majorly ovarian, breast, and prostate cancers. The demand for PARP inhibitors has grown subsequently in past few years, driven by their unique mechanism of action which exploits cancer cells' DNA repair weaknesses. This blog delves into the rising clinical trials and combination therapies in PARP inhibitors, highlighting recent company trials, investment news, and product launches. According to the UnivDatos Market Insights analysis, The PARP Inhibitors Market was valued at USD 4723.5 Million and is expected to grow at a strong CAGR of around 12.9% during the forecast period (2024-2032) . For More Detailed Analysis in PDF Format, Visit- https://univdatos.com/get-a-free-sample-form-php/?product_id=62523 The Mechanism of PARP Inhibitors PARP inhibitors work by inhibiting the PARP enzyme, crucial for repairing single-strand breaks in DNA. When PARP is inhi...